Enabling Breakthrough Immunotherapies via Novel Routes of Drug Delivery

NASDAQ: TLSA

tiziana LIFE SCIENCES

Disclaimer and Forward-Looking Statement

The content of this presentation has been prepared for the purpose of providing general information about, and an overview of, the Company and its business. It is not intended to be a complete review of all matters concerning the Company and nor has it been independently verified. Whilst the presentation has been prepared in good faith and the Company has taken all reasonable care to ensure the information and facts contained in this presentation are accurate and up-to-date, it does not make any representation or warranty, express or implied, as to the accuracy or completeness of any information included in this presentation. Neither the Company nor any of its directors, officers, employees or agents shall be liable for any loss arising directly or indirectly from the use of or reliance upon this presentation or in relation to the adequacy, accuracy, completeness or reasonableness of the information it contains. All and any such liability is expressly excluded to the fullest extent permitted by law. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice.

This presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities including ordinary shares in the Company nor does it constitute an invitation or inducement to engage in investment activity in relation to any securities, including the ordinary shares of the Company. It does not purport to contain information that shall form the basis of or be relied upon in making such investment decisions. If you require any advice, please consult with a professional financial adviser. All investments are subject to risk. The value of securities may go down as well as up. Past performance cannot be relied on as a guide for future performance. This presentation may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this presentation.

Investment Highlights

Innovative, clinically-validated, drug delivery platform enabling improved delivery routes for immunotherapies.
Recent clinical data support the MOA

Global IP protection of antibody formulation technology until 2040, can be applied across different molecules
Strong IP protection for lead assets Milciclib and Foralumab

Partnership with Precision Biosciences for lymphodepletion ahead of CAR-T procedures.
Collaboration ongoing

Targeting the global $150+ billion market for antibody treatments[1]
Clinical data validate MOA for nasal administration

Experienced scientific advisory board and management team that has brought four drugs to market
Demonstrated Bench to market experience

Source: [1] Lu et al. Journal of Biomedical Science (2020) 27:1

A Revolutionary Platform

Antibody Administration: Switching From IV and SC To Oral, Nasal And Inhaled Routes

Today's Options for Antibody Administration are Subcutaneous or Intravenous (IV)



tiziana

The platform enables…

Foralumab
Oral administration
For Crohn's Disease
IBD

Foralumab
Nasal administration
Multiple Sclerosis
Neurodegenerative diseases

TZLS- 501 Anti- IL6R
Direct delivery to lungs with a portable inhaler for pulmonary diseases

Benefits of non-systemic dosing

- Improved patient compliance
- Local activity instead of systemic distribution; may minimize side effects
- Anticipated lower cost of goods and lower price of administration

Our Pipeline of Novel Immunotherapies and Oncology

Four Clinical Studies With Positive data completed 2019-2020

	Subject	PC	IND	Phase 1/IAP	Phase 2	Phase 3
FORALUMAB *Fully human anti-CD3 mAb*	Intranasal	Progressive Multiple Sclerosis (expanded program)			Ongoing IAP trial	
	Intranasal	COVID-19			First ever validation of mechanism of action through immunomodulation	
	Oral	Enteric Coated Oral Capsules for Crohn's Disease			**Completed** (Submitted Phase 1b amended protocol)	
	Subcutaneous	Type 1 Diabetes			1Q-2022 IND Submission	
MILCICLIB *Pan-CDK inhibitor*	Oral	Milciclib + Gemcitabine in Refractory Solid Tumors			**Completed: Strong clinical response in NSCLC**	
	Oral	KRAS+ NSCLC (Milciclib + Gemcitabine)			1Q-2022 IND Submission (new indication)	
	Oral	HCC monotherapy in Sorafenib Resistant Patients				**Asset only/Partnership consideration for Asia-Pacific territory**

*Immune response dependent (and not dependent on viral strain)

Lead Program

Foralumab

The only **fully human** anti-CD3 monoclonal antibody in clinical studies



Non-FC binding anti-CD3 antibody mutations expected to have improved safety profile

Foralumab is the Only Fully Human Anti-CD3 mAb in Clinical Trials

CD3-specific Monoclonal Antibodies in Clinical Development

OKT3 Muromonab*	ChAglyCD3 tOtelixizumab	(Ala-Ala) hOKT3γ1 Teplizumab	Nuvion Visilizumab	**Foralumab**
				
IgG2a	IgG1 N297/A	IgG2 L234/A, L235A	IgG2 L234/A, V237/A	**IgG1** L234/A, V335E
Fully Murine	Chimeric & Humanized	Humanized	Humanized	**Fully Human**

*Approved by the FDA for solid organ transplantation immuno-suppression

Rodent Origin

Human Origin * Point Mutation

First-Ever Patent Granted for Oral Immunotherapy

Adapted from: Kuhn, Chantal, and Howard L. Weiner. "Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside." Immunotherapy 8.8 (2016): 889-906.

Precision Biosciences (Nasdaq: DTIL) Licensing Collaboration Validates Our Technology

First Foralumab Program to be Tested Will be in Combination with an Anti-CD19 CAR-T

Announced September 2, 2021

- Exclusive agreement allowing Precision to explore Tiziana's fully human anti-CD3 monoclonal antibody (mAb), foralumab, as an agent to induce tolerance of allogeneic CAR-T cells to potentially improve the clinical outcome of Precision's CAR-T cell therapy programs
- Foralumab to be used as a potential mild pre-conditioning and lymphodepleting agent to replace or reduce doses of cyclophosphamide/fludarabine (Cy/Flu)

Upfront payments

- Multiple payments commensurate with meeting specified successful milestones
- Royalties
- Additional royalty options for subsequently developed CAR-T products
- Precision to be responsible for the development, commercialization and costs for use of foralumab

Intranasal Foralumab for Treatment of Neurodegenerative Diseases (Multiple Sclerosis)

Local activity with improved safety and lowered dosing

Fully Human

Anti-CD3 mAb

Intranasal

Intranasally-Administered Foralumab Acts via Site Targeted Immunomodulation

An Innovative Approach to Penetrate the Blood-Brain Barrier (BBB)



Clinical studies supporting this MOA

1. Phase 1 trial in healthy volunteers
2. Exploratory trial in Covid-19
3. Ongoing clinical study in secondary progressive multiple sclerosis (SPM)

Foralumab: Clinical Proof of Concept For Intranasal Delivery First Demonstrated in Mild-to-Moderate COVID-19 Model

First Validation that Intranasally Administered Foralumab is Well-tolerated and the Treatment Provides Clinical Benefits via Immunomodulation



CT Scan of Patients' Lungs



Results: Biomarkers measured via cytokines and C-reactive proteins

Cohort *Evaluable patients*	Lung CT Scan *% Improvement*	Cytokine IL-6 *% Reduction*	C-Reactive Protein *% Reduction*
Control, n=14	*43*	*37*	*40*
Foralumab + Dexa, n=12	*75*	*41*	*55*
Foralumab, n=10	**80**	**69**	**85**

Ongoing Multiple Sclerosis Trial with Intranasally Administered Foralumab under the Individual Access Program

- Chronic dosing for at least 6 months is necessary for achieving meaningful clinical responses in Secondary Progressive Multiple Sclerosis (SPMS). FDA allowed 6 months of dosing under an Individual expanded access program (IAP).

- Clinical data from the first patient, after completing 3 out of 6 months, suggested that the treatment was well tolerated with a favorable clinical response. Patient is continuing with the treatment and clinical data after 6 months of dosing will be available Q2 2022

- FDA has allowed enrollment of second patient in trial under this program at the Brigham and Women's Hospital (BWH), Harvard University, Boston, MA

- Investigators at BWH will be monitoring detailed safety, neurological, and Positron Emission Tomography (PET) to evaluate microglial activation in both patients. Modification of immunological and neurodegenerative markers will also be included as part of the standard investigation to be conducted by BWH.

tiziana LIFE SCIENCES

Oral Foralumab for Inflammatory Bowel Diseases (Crohn's Disease)

Local mode of action with improved safety and lowered dosing levels, and enhanced convenience



Oral capsules

Foralumab, a fully human anti-CD3 mAb

Clinical Development of Orally-Administered Foralumab for Crohn's Disease

Phase 1b Trial in Crohn's Disease Patients to Begin Q1 '22



Capsule taken orally

Phase 1a Clinical results

- Foralumab administered at 1.25, 2.5 and 5.0 mg/dose in enteric-coated capsules
- Well-tolerated at all doses tested and no drug-related safety issues observed
- No systemic absorption of orally administered foralumab

Phase 1b Clinical study

An amended IND has been submitted for Phase 1b study with orally administered foralumab in patients with Crohn's Disease

Primary endpoint: safety and tolerability

Secondary endpoints: PK and PD effects

Contact Us

US Headquarters (New York)
Tiziana Therapeutics Inc 3805
Old Easton RD
Doylestown, PA 18902-8400
+ 1 (267) 982 9785

UK Headquarters Tiziana Life
Sciences plc 55 Park Lane
London W1K 1NA United
Kingdom
+44 7769 88 4020

hmalik@tizianalifesciences.com

tiziana
LIFE SCIENCES